Table 2:

Univariate Risk Factors for Recurrence of CDI

	CDI Recurrence
	YES N= 22	NO N=53	P value
Mean Age (±SD)	57.1 ± 18.0	58.5 ± 14.4	0.730
Female (N,%)	15 (68.2%)	37 (69.8%)	0.889
Race (N,%)			0.249
Black	1 (4.5%)	10 (18.9%)
White	18 (81.8%)	38 (71.7%)
Mean BMI (±SD)	28.5 ± 6.6	28.4 ± 6.6	0.969
Received Antibiotics prior to Diagnosis (N,%)	15 (68.2%)	41 (77.4%)	0.405
Antibiotic Type			0.076
Beta- Lactam	8 (36%)	10 (18.8%)
Fluoroquinolone	1 (4.5%)	14 (26.4%)
Lincosamide	3 (13.6%)	2 (3.7%)
Macrolide	0	2 (3.7%)
Metronidazole	2 (9%)	1 (1.8%)
Nitrofurantoin	0	1 (1.8%)
Peptide Antibiotic	0	5 (9.4%)
Rifamycin	0	1 (1.8%)
Sulfa Drug	1 (4.5%)	2 (3.7%)
None	7 (32%)	15 (28.3%)
Prior PPI use (N, %)	10 (45.5%)	31 (58.5%)	0.301
History of Cirrhosis (N,%)	2 (9.1%)	3 (5.7%)	0.626
Dietary restrictionsN,%			0.248
No	19 (86.4%)	49 (92.5%)
Vegan	1 (4.5%)	0 (0.0%)
Vegetarian	2 (9.1%)	1 (1.9%)
Gluten Free	0 (0.0%)	1 (1.9%)
Lactose Free	0 (0.0%)	2 (3.8%)
Smoking status (N,%)			0.220
Never	15 (68.2%)	24 (46.2%)
Former	6 (27.3%)	25 (48.1%)
Current	1 (4.5%)	3 (5.8%)
Diagnosis of Irritable Bowel Syndrome (N,%)	0 (0.0%)	8 (16.3%)	0.051
Baseline diarrhea or constipation (N,%)			0.575
No	18 (81.8%)	36 (70.6%)
Diarrhea	1 (4.5%)	7 (13.7%)
Constipation	2 (9.1%)	7 (13.7%)
Both	1 (4.5%)	1 (2.0%)
Baseline Bristol Score (±SD)	2.7 ± 1.2	3.3 ± 1.2	0.084
Ursodiol Use (N,%)	0 (0.0%)	0 (0.0%)	0.0
Cholestyramine Use (N,%)	2 (9.1%)	0 (0.0%)	0.085
Colestipol Use (N,%)	0 (0.0%)	1 (1.9%)	1.0
CDI Treatment Regimen (N,%)			0.030
Metronidazole	9 (40.9%)	8 (15.1%)
Vancomycin	13(59.1%)	45 (84.9%)
Test Used for Diagnosis (N,%)			0.007
PCR	5 (22.7%)	30 (56.6%)
EIA Toxin	17 (77.3%)	23 (43.4%)
Mean White Blood Cell Count (±SD)	8.2 ± 3.3	14.8 ± 18	0.147
Mean Platelet Count (±SD)	206.3 ± 72.	270.9 ± 114.8	0.030